The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

Efficacy and safety of insulin degludec

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

✍ Zinman, Bernard; DeVries, J Hans; Bode, Bruce; Russell-Jones, David; Leiter, Law 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 337 KB

Low-Volume Insulin Degludec 200 Units/mL

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial

✍ Gough, S. C. L.; Bhargava, A.; Jain, R.; Mersebach, H.; Rasmussen, S.; Bergensta 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 443 KB

Efficacy and safety of a fixed-ratio com

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sulta 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 284 KB

Efficacy and safety of a fixed-ratio com

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

✍ Gough, Stephen C L; Bode, Bruce; Woo, Vincent; Rodbard, Helena W; Linjawi, Sulta 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 284 KB

## Background: A fixed-ratio combination of the basal insulin analogue insulin degludec and the glucagon-like peptide-1 (glp-1) analogue liraglutide has been developed as a once-daily injection for the treatment of type 2 diabetes. we aimed to compare combined insulin degludec-liraglutide (ideglira

Efficacy and Safety Profile of Exenatide

Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study

✍ Inagaki, Nobuya; Atsumi, Yoshihito; Oura, Tomonori; Saito, Hitoshi; Imaoka, Take 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 962 KB

28-week, randomized, multicenter, open-l

28-week, randomized, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes

✍ Takashi Kadowaki; Tomoyuki Nishida; Kohei Kaku 📂 Article 📅 2010 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 201 KB